Antibe Therapeutics Inc. (TSE:ATE – Get Rating) Senior Officer Scott Wilson Curtis acquired 20,000 shares of the firm's stock in a transaction dated Friday, July 8th. The stock was purchased at an average cost of C$0.62 per share, with a total value of C$12,400.00. Following the completion of the acquisition, the insider now directly owns 80,000 shares of the company's stock, valued at approximately C$49,600.
ATE stock opened at C$0.62 on Wednesday. The company has a market capitalization of C$31.86 million and a P/E ratio of -1.16. Antibe Therapeutics Inc. has a twelve month low of C$0.59 and a twelve month high of C$3.65. The business has a 50 day simple moving average of C$0.66 and a 200-day simple moving average of C$0.70. The company has a current ratio of 13.07, a quick ratio of 11.92 and a debt-to-equity ratio of 0.29.
Get Antibe Therapeutics alerts:About Antibe Therapeutics (Get Rating)
Antibe Therapeutics Inc, a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.Read More
- Should These Two Airlines Be In Your Portfolio?
- Old Dominion Freight Line (ODFL): This Dividend Growth Stock Deserves Your Attention
- Is There a Reasonable Price to Buy Stitch Fix Stock?
- 3 Smid Caps Under $20 Set to Recover
- Continuining to Assess Tesla's Future As The EV Market Becomes Increasingly Competitive
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.